Dr. Reddy’s says India’s drug regulator (DCGI) has approved Zytorvi for use in esophageal cancer. The approval expands the drug’s use beyond its earlier indication in nasopharyngeal carcinoma, making it the second approved indication in India.
Outlets frame the news as an additional step for the treatment option in cancer care. The Hindu highlights that the approval broadens the use of Zytorvi, which is linked to Shanghai Junshi Biosciences’ drug platform. Business Line specifies the clinical scope more precisely, describing it as a first-line option for adult patients with certain advanced esophageal squamous cell carcinoma disease characteristics. Economic Times presents the same approval headline but provides fewer details in the material provided.
